Mabthera Iv Range 100 mg. 500 mg Infusion
PDF Leaflet Revision Date: 12 October 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of CD20-positive B-cell malignancies.
Dosage (summary)
375 mg/mu00b2 IV infusion weekly for 4 doses for NHL; 1000 mg IV infusion twice for RA.
Onset of Action / Duration
Onset: 30 mins, Duration: variable
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; unknown if excreted in breast milk.
Key Drug Interactions
- Methotrexate
- Fludarabine
- Cyclophosphamide
Contraindications
- Hypersensitivity
- Active severe infections
- Severe heart failure
Common side effects
- Infusion-related reactions
- Infections
- Neutropenia
Counselling Points
- Monitor for infusion reactions
- Avoid live vaccines
- Use contraception during treatment
Serious warnings
- Severe infusion-related reactions
- Tumour lysis syndrome
- Progressive multifocal leukoencephalopathy
Important Disclaimer
The Mabthera Iv Range 100 mg. 500 mg Infusion professional information leaflet below is the property of Roche Products and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
